Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin

Kateřina Kuželová, Michaela Pluskalová, Barbora Brodská, Petra Otevřelová, Klára Elknerová, Dana Grebeňová, Zbyněk Hrkal

Jazyk angličtina Země Spojené státy americké

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12008650

Grantová podpora
NR9243 MZ0 CEP - Centrální evidence projektů

Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) which is being introduced into clinic for the treatment of hematological diseases. We studied the effect of this compound on six human hematopoietic cell lines (JURL-MK1, K562, CML-T1, Karpas-299, HL-60, and ML-2) as well as on normal human lymphocytes and on leukemic primary cells. SAHA induced dose-dependent and cell type-dependent cell death which displayed apoptotic features (caspase-3 activation and apoptotic DNA fragmentation) in most cell types including the normal lymphocytes. At subtoxic concentrations (0.5-1 microM), SAHA increased the cell adhesivity to fibronectin (FN) in all leukemia/lymphoma-derived cell lines but not in normal lymphocytes. This increase was accompanied by an enhanced expression of integrin beta1 and paxillin, an essential constituent of focal adhesion complexes, both at the protein and mRNA level. On the other hand, the inhibition of ROCK protein, an important regulator of cytoskeleton structure, had no consistent effect on SAHA-induced increase in the cell adhesivity. The promotion of cell adhesivity to FN seems to be specific for SAHA as we observed no such effects with other HDAC inhibitors (trichostatin A and sodium butyrate).

Citace poskytuje Crossref.org

000      
03103naa a2200469 a 4500
001      
bmc12008650
003      
CZ-PrNML
005      
20140722124719.0
008      
120316s2010 xxu eng||
009      
AR
024    __
$a 10.1002/jcb.22397 $2 doi
035    __
$a (PubMed)19911379
040    __
$a ABA008 $b cze $d ABA008
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kuželová, Kateřina $7 xx0115456 $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic. kuzel@uhkt.cz
245    10
$a Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin / $c Kateřina Kuželová, Michaela Pluskalová, Barbora Brodská, Petra Otevřelová, Klára Elknerová, Dana Grebeňová, Zbyněk Hrkal
520    9_
$a Suberoylanilide hydroxamic acid (SAHA) is an inhibitor of histone deacetylases (HDACs) which is being introduced into clinic for the treatment of hematological diseases. We studied the effect of this compound on six human hematopoietic cell lines (JURL-MK1, K562, CML-T1, Karpas-299, HL-60, and ML-2) as well as on normal human lymphocytes and on leukemic primary cells. SAHA induced dose-dependent and cell type-dependent cell death which displayed apoptotic features (caspase-3 activation and apoptotic DNA fragmentation) in most cell types including the normal lymphocytes. At subtoxic concentrations (0.5-1 microM), SAHA increased the cell adhesivity to fibronectin (FN) in all leukemia/lymphoma-derived cell lines but not in normal lymphocytes. This increase was accompanied by an enhanced expression of integrin beta1 and paxillin, an essential constituent of focal adhesion complexes, both at the protein and mRNA level. On the other hand, the inhibition of ROCK protein, an important regulator of cytoskeleton structure, had no consistent effect on SAHA-induced increase in the cell adhesivity. The promotion of cell adhesivity to FN seems to be specific for SAHA as we observed no such effects with other HDAC inhibitors (trichostatin A and sodium butyrate).
590    __
$a bohemika - dle Pubmed
650    02
$a antigeny CD29 $7 D019012
650    02
$a protinádorové látky $x farmakologie $7 D000970
650    02
$a apoptóza $7 D017209
650    02
$a western blotting $7 D015153
650    02
$a buněčná adheze $x účinky léků $7 D002448
650    02
$a nádorové buněčné linie $7 D045744
650    02
$a separace buněk $7 D002469
650    02
$a fibronektiny $x metabolismus $7 D005353
650    02
$a průtoková cytometrie $7 D005434
650    02
$a lidé $7 D006801
650    02
$a kyseliny hydroxamové $x farmakologie $7 D006877
650    02
$a leukemie $x metabolismus $7 D007938
650    02
$a lymfocyty $x metabolismus $x účinky léků $7 D008214
650    02
$a paxilin $x metabolismus $7 D051419
650    02
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pluskalová, Michaela $7 xx0115460 $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Brodská, Barbora $7 xx0161159 $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Otevřelová, Petra $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1#
$a Elknerová, Klára $7 _AN050620 $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Grebeňová, Dana $7 xx0115458 $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Hrkal, Zbyněk, $d 1934- $7 xx0059987 $u Department of Cellular Biochemistry, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
773    0_
$t Journal of Cellular Biochemistry $p J Cell Biochem $g Roč. 109, č. 1 (2010), s. 184-195 $w MED00002577 $x 0020-8868
773    0_
$p J Cell Biochem $g 109(1):184-95, 2010 Jan 1
910    __
$a ABA008 $b x $y 4 $z 0
990    __
$a 20120319124606 $b ABA008
991    __
$a 20140722125027 $b ABA008
999    __
$a ok $b bmc $g 901994 $s 765545
BAS    __
$a 3
BMC    __
$a 2010 $b 109 $c 1 $d 184-195 $m Journal of cellular biochemistry $x MED00002577
GRA    __
$a NR9243 $p MZ0
LZP    __
$a 2012-1Q10/

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé